Dose-effect of SSR180575 in Diabetic Neuropathy

NCT00502515 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

309

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetic Neuropathies

Interventions

DRUG: SSR180575
DRUG: Placebo

Sponsor

Sanofi